BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1632 related articles for article (PubMed ID: 18083265)

  • 1. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
    Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
    J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs.
    Dong Y; Feng SS
    Biomaterials; 2005 Oct; 26(30):6068-76. PubMed ID: 15894372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Water-soluble betamethasone-loaded poly(lactide-co-glycolide) hollow microparticles as a sustained release dosage form.
    Chaw CS; Yang YY; Lim IJ; Phan TT
    J Microencapsul; 2003; 20(3):349-59. PubMed ID: 12881115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content.
    Budhian A; Siegel SJ; Winey KI
    Int J Pharm; 2007 May; 336(2):367-75. PubMed ID: 17207944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of process and formulation parameters on characteristics and internal morphology of poly(d,l-lactide-co-glycolide) microspheres formed by the solvent evaporation method.
    Mao S; Shi Y; Li L; Xu J; Schaper A; Kissel T
    Eur J Pharm Biopharm; 2008 Feb; 68(2):214-23. PubMed ID: 17651954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, characterization, and in vitro evaluation of physostigmine-loaded poly(ortho ester) and poly(ortho ester)/poly(D,L-lactide-co-glycolide) blend microspheres fabricated by spray drying.
    Wang L; Chaw CS; Yang YY; Moochhala SM; Zhao B; Ng S; Heller J
    Biomaterials; 2004 Jul; 25(16):3275-82. PubMed ID: 14980422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles.
    Zhao A; Rodgers VG
    J Control Release; 2006 Jun; 113(1):15-22. PubMed ID: 16707186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro study of anticancer drug doxorubicin in PLGA-based microparticles.
    Lin R; Shi Ng L; Wang CH
    Biomaterials; 2005 Jul; 26(21):4476-85. PubMed ID: 15701377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles.
    Kumar PS; Ramakrishna S; Saini TR; Diwan PV
    Pharmazie; 2006 Jul; 61(7):613-7. PubMed ID: 16889069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution.
    Mainardes RM; Evangelista RC
    Int J Pharm; 2005 Feb; 290(1-2):137-44. PubMed ID: 15664139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thermal behavior and stability of biodegradable spray-dried microparticles containing triamcinolone.
    da Silva AA; de Matos JR; Formariz TP; Rossanezi G; Scarpa MV; do Egito ES; de Oliveira AG
    Int J Pharm; 2009 Feb; 368(1-2):45-55. PubMed ID: 18992313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon.
    Krishnamachari Y; Madan P; Lin S
    Int J Pharm; 2007 Jun; 338(1-2):238-47. PubMed ID: 17368982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Versatility of biodegradable poly(D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery.
    Díez S; Tros de Ilarduya C
    Eur J Pharm Biopharm; 2006 Jun; 63(2):188-97. PubMed ID: 16697172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality.
    McCarron PA; Marouf WM; Donnelly RF; Scott C
    J Biomed Mater Res A; 2008 Dec; 87(4):873-84. PubMed ID: 18228271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method.
    Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
    Colloids Surf B Biointerfaces; 2009 Nov; 74(1):340-9. PubMed ID: 19717287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
    Liu SQ; Tong YW; Yang YY
    Biomaterials; 2005 Aug; 26(24):5064-74. PubMed ID: 15769542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers.
    Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC
    J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation behaviour in vitro for poly(D,L-lactide-co-glycolide) as drug carrier.
    Lee JS; Chae GS; Kim MS; Cho SH; Lee HB; Khang G
    Biomed Mater Eng; 2004; 14(2):185-92. PubMed ID: 15156109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
    Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
    Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method.
    Choi SH; Park TG
    Int J Pharm; 2006 Mar; 311(1-2):223-8. PubMed ID: 16423477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.